Further pharmacological validation of the BALB/c neophobia in the free exploratory paradigm as an animal model of trait anxiety

Behavioural Pharmacology

Volumn 8, Issue 6-7, 1997, Pages 541-548

  Belzung, C ^a   Berton, F ^a  

^a Lab d'Ethol Pharmacologie Comport   (France)

Author keywords

Anxiolytics; BALB c mice; Free exploratory paradigm; Generalized anxiety; Trait anxiety

Indexed keywords

ALCOHOL; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE; CHLORDIAZEPOXIDE; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; DIZOCILPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; IDAZOXAN; MEPROBAMATE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PENTOBARBITAL; RITANSERIN; SEROTONIN 2 ANTAGONIST; SULPIRIDE; YOHIMBINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ANXIETY NEUROSIS; ARTICLE; CONTROLLED STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; MOUSE; NEOPHOBIA; NONHUMAN;

EID: 0030781583     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008877-199711000-00012     Document Type: Article

References (47)

1. Ågmo A, Galvan A, Heredia A and Morales M (1995) Naloxone blocks the antianxiety but not the motor effects of benzodiazepines and pentobarbital: experimental studies and literature review. Psychopharmacology, 120, 186-194.
2. Belzung C and Le Pape G (1994) Comparison of different behavioral test situations used in psychopharmacology for the measurement of anxiety. Physiology and Behavior, 56, 623-628.
3. Belzung C, Misslin R, Vogel E, Dodd RH and Chapouthier G (1987) Anxiogenic effects of methyl-β-carboline-3-carboxylate in a light/dark choice situation. Pharmacolology Biochemistry and Behavior, 28, 29-33.
4. Belzung C, Pineau N, Beuzen A and Misslin R (1994) The effectiveness of PD 135158, a selective CCK-B receptor antagonist, in reducing "state" but not "trait" anxiety in BALB/c mice. Pharmacology Biochemistry and Behavior, 49, 433-436.
5. Beuzen A and Belzung C (1995) Link between emotional memory and anxiety states: a study by principal component analysis. Physiology and Behavior. 58, 111-118.
6. Boissier JR and Simon P (1964) Dissociation de deux composantes dans le comportement d'investigation de la souris. Archives Internationales de Pharmacodynamie et de Thérapie, 147, 372-387.
7. Brinkley JR, Beitman BD and Friedel RO (1979) Low doses neuroleptic regimens in the treatment of borderline patients. Archives of General Psychiatry, 36, 319-326.
8. Ceulemans DLS, Hoppenbrouwers MLJA, Gelders YG and Reyntjens AJM (1985) The influence of ritanserin, a serotonergic antagonist, in anxiety disorders: a double blind placebo-controlled study versus lorazepam. Pharmacopsychiatry, 8: 303-305.
9. Charney DS, Heninger GR and Breier A (1984) Noradrenergic function in panic anxiety: effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Archives of General Psychiatry, 41, 751-763.
10. Cole JC, Burroughs GJ, Laverty CR, Sheriff NC, Sparham EA and Rodgers RJ (1995) Anxiolytic-like effects of yohimbine in the murine plus-maze: strain independence and evidence against alpha 2-adrenoceptor mediation. Psychopharmacology, 118, 425-436.
11. Crawley JN (1981) Neuropharmacologic specificity of a simple animal model for the behavioural actions of benzodiazepines. Pharmacology Biochemistry and Behavior, 15, 695-699.
12. 2 receptors. Psychopharmacology, 93, 502-506.
13. Deakin JFW, Wang M and Guimaraes FS (1991) Clinical Experience with Ritanserin, Adis International Press, pp. 16-33.
14. De Vry J, Benz U, Schreiber R and Traber J (1993) Shock-induced ultrasonic vocalization in young adult rats: a model for testing putative anti-anxiety drugs. European Journal of Pharmacology, 249, 331-339.
15. DSM IV (1994) American Psychiatric Association.
16. 2 receptor and fluvoxamine effect in obsessive-compulsive disorder. Human Psychopharmacology, 7, 287-289.
17. File SE (1980) The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs. Journal of Neuroscience Methods, 2, 219-238.
18. File SE and Johnston AL (1987) Chronic treatment with imipramine does not reverse the effects of 3 anxiogenic compounds in a test of anxiety in the rat. Neuropsychobiology, 17, 187-192.
19. Finnerty RJ, Goldberg HL, Nathan L, Lowrey C and Cole JO (1976) Haloperidol in the treatment of psychoneurotic anxious outpatients. Diseases of the Nervous System, 37, 621-624.
20. Gardner CR (1985) Inhibition of ultrasonic distress vocalizations in rat pups by chlordiazepoxide and diazepam. Drug Development Research, 5, 185-193.
21. Garfield S, Gershon S, Sletten I et al. (1967) Chemically induced anxiety. International Journal of Neuropsychology, 3, 426-433.
22. Geller I and Seifter J (1960). The effects of meprobamate, barbiturates, d-amphetamine and promazine on experimentally induced conflict in the rat. Psychopharmacology, 1, 482-492.
23. Griebel G, Belzung C, Misslin R and Vogel E (1993) The free exploratory paradigm: an effective method for measuring neophobic behavior in mice and testing potential neophobia reducing drugs. Behavioural Pharmacology, 4, 637-644.
24. Haefely W, Schaffner R, Pole P and Pieri L (1981) General pharmacology and neuropharmacology of propanediol carbamates. In: Handbook of Experimental Pharmacology, Vol 55/II (Eds F Hoffmeister and G Stille), pp. 263-283. Springer Verlag, Berlin.
25. Handley SL (1995) 5-Hydroxytryptamine pathways in anxiety and its treatment. Pharmacology and Therapeutics, 66, 103-148.
26. Handley SL and Mithani S (1984) Effects of alpha-adrenoceptor agonists and antagonists in a maze-exploration model of "fear"-motivated behaviour. Naunyn-Schmiedebergs Archives of Pharmacology, 327, 1-5.
27. Johnston AL and File SE (1989) Yohimbine's anxiogenic action: evidence for noradrenergic and dopaminergic sites. Pharmacology Biochemistry and Behavior, 32, 151-156.
28. Lister RG (1990) Ethologically based animal models of anxiety disorders. Pharmacology and Therapeutics, 46, 321-340.
29. 35S]t-butylbicyclophosphorothionate binding differentiates convulsant and depressant drugs that modulate GABAergic transmission. Journal of Neurochemistry, 44, 480-486.
30. Misslin R and Cigrang M (1986) Does neophobia necessarily imply fear or anxiety? Behavioural Processes, 12, 45-50.
31. Misslin R, Ropartz P and Jung L (1984) Impairment of responses to novelty by apomorphine and its antagonism by neuroleptics in mice. Psychopharmacology, 82, 113-117.
32. Pellow S, Chopin P, File SE and Briley M (1985) Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. Journal of Neuroscience Methods, 14, 149-167.
33. Pellow S, Johnston AL and File SE (1987) Selective agonists and antagonists for 5-hydroxytryptamine receptor subtypes, and interactions with yohimbine and FG 7142 using the elevated plus maze test in the rat. Journal of Pharmacy and Pharmacology, 39, 917-928.
34. Rodgers RJ, Nikulina EM and Cole JC (1994) Dopamine D1 and D2 receptor ligands modulate the behaviour of mice in the elevated plus-maze. Pharmacolology, Biochemistry and Behavior, 49, 985-995.
35. Schweizer E, Csanalosi I and Rickels K (1988) Pilot study of alpidem, a new non-benzodiazepine anxiolytic, in the treatment of generalized anxiety disorder. Journal of Clinical Pharmacology, 8, 74.
36. Skerritt JH and Johnston GA (1983) Interactions of some anaesthetics, convulsant and anticonvulsant drugs at GABA-benzodiazepine receptor ionophore complexes in rat brain synaptosomal membranes. Neurochemical Research, 8, 1351-1362.
37. Spielberger CD (1975) The measurement of state and trait anxiety: conceptual and methodological issues. In: Emotions: their Parameters and Measurement (Ed. Levi L), pp. 713-725. Raven Press, New York.
38. Taukulis HK (1996) Pavlovian conditioning to a diazepam cue with yohimbine as the unconditional stimulus. Neurobiology of Learning and Memory, 65, 223-232.
39. Thiébot MH, Soubrie P, Simon P and Boissier JR (1973) Dissociation de deux composantes du comportement chez le rat sous l'effet de psychotropes. Application à l'étude des anxiolytiques. Psychopharmacology, 31, 77-90.
40. Thiébot MH, Dangoumau L, Richard G and Puech AJ (1991) Safety signal withdrawal paradigm sensitive to both "anxiolytic" and "anxiogenic" drugs under identical experimental conditions. Psychopharmacology, 103, 415-424.
41. Ticku MK and Kulkarni SK (1988) Molecular interactions of ethanol with GABAergic system and potential of RO 154513 as an ethanol antagonist. Pharmacology, Biochemistry and Behavior, 30, 501-510.
42. Ticku MK and Rastogi SK (1980) Barbiturate-sensitive sites in the benzodiazepine-GABA receptor-ionophore complex. In: Molecular and Cellular Mechanisms of Anaesthetics (Eds SH Roth and WK Miller), pp. 179-188. Plenum Press, New York.
43. Treit D (1985) Animal models for the study of anti-anxiety agents: a review. Neuroscience and Biobehavioural Review, 9, 203-222.
44. Vogel JR, Beer B and Clody DE (1971) A simple and reliable conflict procedure for testing antianxiety agents. Psychopharmacologia, 21, 1-7.
45. Wada T and Fukuda N (1991) Effects of DN-2327, a new anxiolytic, diazepam and buspirone on exploratory activity of the rat in an elevated plus-maze. Psychopharmacology, 104, 444-450.
46. Wiley JL and Balster RL (1993) NMDA antagonists: a novel class of anxiolytics? In: Anxiety: Neurobiology, Clinic and Therapeutic Perspectives (Eds M Hamon, H Ollat and MH Thiébot), pp. 177-184. John Libbey Eurotext Ltd., Colloque INSERM.
47. Wright IK, Heaton M, Upton N and Mardsden CA (1992) Comparison of acute and chronic treatments of various serotonergic agents with those of diazepam and idazoxan in the elevated X-maze. Psychopharmacology, 107, 405-414.